The administration is considering whether to revisit if drug companies’ rebates should be allowed safe harbor from anti-kickback laws in an effort to help curb rising healthcare costs, FDA Commissioner Scott Gottlieb told the Food and Drug Law Institute’s annual meeting in Washington, D.C.
Source: Drug Industry Daily